Intervention (n = 14) | Control (n = 7) | |
---|---|---|
Mean (SD) | Mean (SD) | |
Age at baseline (y) | 63 (5) | 63 (5) |
Age at PC diagnosis (y) | 61 (6) | 63 (6) |
Weight (kg) | 88 (17) | 83 (10) |
Height (m) | 1.83 (0.06) | 1.80 (0.04) |
BMI (kg/m2) | 26.0 (3.4) | 25.6 (2.5) |
Hip circumference (cm) | 105 (10) | 102 (6) |
Waist circumference (cm) | 102 (15) | 98 (6) |
Fat-free mass (kg) | 65 (7) | 64 (6) |
Fat mass (%) | 25 (6) | 23 (4) |
VO2 max (ml O2/min/kg) | 29 (7) | 26 (5) |
Systolic BP (mmHg) | 146 (19) | 142 (13) |
Diastolic BP (mmHg) | 89 (10) | 87 (8) |
HDL cholesterol (mmol/L) | 1.3 (0.2) | 1.3 (0.2) |
LDL cholesterol (mmol/L) | 2.8 (0.7) | 2.9 (0.6) |
Total cholesterol (mmol/L) | 5.1 (0.7) | 5.3 (0.8) |
Triglycerides (mmol/L) | 1.3 (0.4) | 1.5 (0.6) |
Fasting plasma glucose (mmol/L) | 5.8 (0.6) | 6.1 (0.4) |
Fasting blood glucose (mmol/L) | 5.3 (0.5) | 5.6 (0.5) |
Blood glucose 2 h (mmol/L) | 6.7 (2.2) | 8.3 (2.0) |
Fasting insulin (mmol/L) | 11.6 (6.6) | 11.8 (6.8) |
Alkylresorcinols total (nmol/L) | 109 (98) | 74 (39) |
C17:C21 alkylresorcinol ratio | 0.39 (0.19) | 0.30 (0.10) |
Plasma enterolactone (nM) | 51 (51) | 52 (50) |
Prostate-specific antigen (PSA) (ng/ml) | 5.4 (1.7) | 5.0 (2.2) |